Ask AI
Updates in CLL

CE / CME

Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physician Assistants: maximum of 1.00 hour of AAPA Category 1 CME credit

Registered Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: April 22, 2025

Expiration: October 21, 2025

Pretest

Progress
1 2
Course Completed
1.

Which of the following was demonstrated in the interim analysis of results from the phase III AMPLIFY trial of fixed duration Acalabrutinib (A) + Venetoclax (V) ± Obinutuzumab (O) vs FCR/BR for untreated CLL without del(17p) or TP53 mutations?

2.

Patient Case: A 76-Yr-Old Woman With Previously Untreated CLL



  • 76-yr-old woman was diagnosed with CLL in 2023

    • Rai stage 1, IGHV unmutated, FISH reveals del(17p)



  • Patient has a long-standing history of hypertension controlled with 3 medicines, coronary artery disease controlled medically, atrial fibrillation which was controlled, and baseline creatinine of 1.8

  • Initially, patient was followed with watchful waiting but developed PD in 2024

  • Workup revealed Hb of 9.9, white count of 77, and platelet of 90K

  • CT scan revealed bulky axillary nodes of 7 cm bilateral and retroperitoneal nodes of 9 cm

  • Patient has difficulty with mobility due to arthritis and lives 3 hr from the treatment center

  • She is worried about travel requirements and wants to start treatment that gives her the best outcome 

Which of the following would you recommend as the best first-line therapy for this patient?

3.

Patient Case: An 86-Yr-Old Man With Relapsed CLL



  • An 86-yr-old man was diagnosed with CLL in 2013

    • Rai stage 1, IGHV unmutated, FISH reveals trisomy 12



  • S/p prior treatment with bendamustine + rituximab in 2014, followed by venetoclax + rituximab from 2016 to 2018

  • In 2019 he was started on acalabrutinib and achieved good disease control

  • He remained on acalabrutinib but recently developed worsening lymphocytosis and lymphadenopathy concerning for progressive disease

  • NGS revealed acquired BTK C481S mutation

  • He states that he would prefer another oral therapy in his next line of treatment 

Which of the following would you recommend as the best next-line therapy for this patient?